Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01836549
Recruitment Status : Completed
First Posted : April 22, 2013
Last Update Posted : April 12, 2016
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Pediatric Brain Tumor Consortium

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : April 2016
  Actual Study Completion Date : April 2016

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 December 13, 2016
February 6, 2017
2 March 29, 2017
May 8, 2017
3 June 1, 2017
June 30, 2017
4 November 7, 2017
December 8, 2017
5 January 23, 2018
February 20, 2018